Objectives: There is little information about whether use of pain self-management skills that are common targets of psychosocial interventions for pain are associated with reduced reliance on pain medications. The aim of this study was to test whether higher chronic pain acceptance, which is a readily modified pain selfmanagement approach, is related to lower use of pain medications (eg, opioid medications, and gabapentinoids) in a sample with chronic pain and spinal cord injury (SCI). Results: Regression results indicated that, above and beyond the effects of pain intensity, pain distribution, and depressive symptoms, higher pain acceptance was related to lower use of all types of pain medications, and lower odds of using opioid medications or gabapentinoids. Pain intensity was not related to pain medication use, but greater pain distribution was related to using more pain medications in general and to greater odds of using gabapentinoids.
C hronic pain is very common after spinal cord injury (SCI), with a prevalence of ∼65%. [1] [2] [3] Pain, which is often rated as "severe" or "excruciating," 1-3 is associated with adverse effects on well-being, function, and quality of life 1, [4] [5] [6] [7] [8] and is considered the most disabling secondary condition in SCI. 9 Similar to other chronic pain populations, various treatment modalities, including use of multiple pain medications (eg, opioid and nonopioid analgesics, anticonvulsants) are typically used, but are often insufficient for resolving pain in persons with SCI. 1, 10, 11 Lack of efficacy as well as negative side-effects are reasons that many with chronic pain and SCI try and discontinue numerous pain medications in search of pain relief. 10, [12] [13] [14] There is mounting concern about overuse of pain medications, particularly for chronic pain. Although most of this concern has focused on opioids, which are associated with significant morbidity and mortality as well as poor efficacy for chronic pain, [15] [16] [17] other pain medications also present significant risks. For instance, nonsteroidal antiinflammatory drugs (NSAIDs) present the risk for toxicityrelated stomach upset, gastrointestinal bleeding, and kidney failure. 18, 19 Antiepileptics, which are commonly used to treat neuropathic pain in SCI, can be accompanied by a number of side-effects, such as fatigue, dizziness, unsteadiness, somnolence, dry mouth, swelling, gastrointestinal problems, and cognitive dysfunction. 13, 20 In addition to these concerns about pain medications in the general population, there are reasons for specific concerns about pain medication use in those with SCI. Persons with SCI may be particularly sensitive to central nervous system-related sideeffects that are especially common to opioid and antiepileptic drugs (eg, gabapentin), possibly due to concomitant use of other centrally acting agents to address other problems, such as neurogenic bladder and spasticity. 21 SCI can make it difficult for some individuals to detect stomach upset related to NSAIDs or other medications and opioid-induced constipation 22, 23 can present a particular challenge to those with compromised bowel functioning (ie, neurogenic bowel dysfunction). Furthermore, the extant literature suggests a synergistic effect between the pathophysiology of SCI and the use of opioid medications that can increase the risk for worsening pain, locomotor deficits, infections, and mortality. 24 Despite these concerns, a survey of persons with SCI suggested an increase in the number of pain medications used over time, with no change in pain severity. 14 Taken together, these findings indicate a clear need for effective nonpharmacological alternatives to reduce reliance on all types of pain medications in those with chronic pain and SCI.
Psychological interventions for chronic pain, including so-called "third wave" behavioral therapies such as Acceptance and Commitment Therapy (ACT) and mindfulness-based stress reduction (MBSR), are associated with reduced pain intensity and improved physical and emotional function. 12, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] When used to treat chronic pain, interventions such as ACT and MBSR typically include a treatment component that focuses on increasing pain acceptance, commonly defined as the willingness to experience pain (pain willingness) coupled with engagement in valued-life activities (activities engagement). [37] [38] [39] Interestingly, multidisciplinary pain treatment programs that are not acceptance-focused, per se, as well as the aforementioned acceptance-based interventions have been shown to increase pain acceptance. [28] [29] [30] [31] [32] [33] [34] [35] 40 In addition, there is a robust body of observational research showing that greater acceptance of pain is associated with lower emotional distress and better physical and psychosocial functioning in multiple chronic pain conditions, [41] [42] [43] [44] [45] [46] [47] [48] [49] and with lower pain interference, depression, and higher functioning and quality of life in persons with SCI. [50] [51] [52] These data are encouraging as to the positive effects of psychological pain interventions generally and of the benefits of pain acceptance specifically. In the context of a growing interest in reducing pain medication use, it is also important to determine whether one of the outcomes of psychological approaches to pain management is a reduced reliance on pain medication. Although this is one of the assumed benefits, studies on the association between pain coping or self-management interventions and reliance on pain medication are lacking. Data on the effects of behavioral intervention on pain medication use are sparse and equivocal, [53] [54] [55] and there are no known studies that examine this in the context of SCI. The question of whether pain acceptance is specifically related to lower reliance on pain medications in any clinical population has also not been investigated. Because willingness to experience pain coupled with a deemphasis on reduction/control of pain are foundational aspects of pain acceptance, 56 it is plausible that acceptance of pain may be an especially important construct to investigate as it relates to pain medication use. Such knowledge can inform treatment planning and patient-specific tailoring of psychological pain interventions.
The purpose of this study was to examine the association between levels of pain acceptance and medication use in a sample of persons with chronic pain and SCI. Our hypothesis was that those with higher pain acceptance would use fewer pain medications, controlling for pain intensity, pain distribution (number of pain sites on the body), and level of depressive symptoms. In examining this association, we considered whether pain acceptance related to the use of a number of different types of medications that are commonly used for chronic pain management, opioid medications alone, and gabapentinoids (ie, gabapentin or pregabalin) alone; these drugs were singled out due to their high rate of use in SCI and their especially high risk for serious sideeffects. We also examined whether one of the components of pain acceptance, pain willingness, or activities engagement, was the main driver of these associations, with the expectation that pain willingness would be more strongly associated with pain medication use than activities engagement.
MATERIALS AND METHODS

Participants
Participants with SCI and chronic pain participated in this study. Potential volunteers were told that this was a study of chronic pain in SCI and asked whether they had "chronic pain" (not further operationalized) and were interested in participating. Inclusion criteria were: (1) 18 years of age and above; (2) ≥ 4/10 average pain in the past month on a 0 "no pain" to 10 "worst imaginable pain" scale, which is typically recommended as the minimum score to screen for "clinically significant," at least "moderate" pain that interferes with daily functioning; [57] [58] [59] [60] [61] [62] (3) SCI diagnosis (confirmed by medical record review); (4) ≥ 1 year since SCI; (5) able to use the study device (ie, use a touchscreen or computer mouse and push a button on a wristwatch with finger of opposing hand); (6) able to converse fluently in English; and (7) able to read at the 6th grade level. Participants were excluded from participating if they had atypical wake/sleep patterns (eg, shift work) or were currently receiving inpatient rehabilitation or hospitalization.
Study Procedures
This is a secondary analysis of cross-sectional data from a study that examined the role of pain acceptance in the day-to-day experiences of people with chronic pain and SCI. The study included a 7-day home monitoring period where participants continuously wore an accelerometer, provided real-time self-report of pain and pain interference 5 times a day, and completed end-of-day online surveys each of the 7 nights. Data from the baseline survey measures were analyzed for this study. Details on the full-study methodology can be found in earlier papers. 51, 63 Three sites collaborated to collect these data: University of Michigan (UM) in Ann Arbor, MI, Wayne State University/Rehabilitation Institute of Michigan (WSU/ RIM) in Detroit, MI, and University of Washington (UW) in Seattle, WA. Institutional Review Board approval was granted before initiation of study activities at each site. Data were collected between June 2014 and January 2016.
Study participants were recruited through placement of flyers in medical centers and community locations, electronic medical records, and existing participant/patient registries. All recruiting was carried out through email or telephone with initial screening conducted over the telephone. Eligible volunteers were then scheduled for an in-person visit where they underwent informed consent procedures. After providing written consent, participants completed an in-laboratory baseline survey battery. Laboratory visits typically lasted about 90 minutes. Participants were also given contact information for study personnel. Participants were compensated $25 for the baseline visit.
Measures
Demographics and Clinical Characteristics
Participants completed a survey of their demographic data (eg, sex, age, education and clinical data. Self-reported clinical data (ie, injury level and severity, date of injury) were confirmed through medical record review.
Medication Use
Medication use was assessed with a medication survey that was part of the demographic form. Respondents were asked to report the name and dosage of prescription medications, over-the-counter medications, and herbal remedies they were currently taking. In addition, study participants were asked, "how frequently do you take the medication?" and to report the "reason for taking the drug." A list of all medications reported by study participants was compiled and reviewed by a physician who treats SCI patients (P.C.).
All pain-relevant prescription and over-the-counter medications were assembled into 9 pain medication categories by drug type to aid in initial assessment of pain medications reported in the sample (see top column of Table 1 ). The total number of pain medications was aggregated to create a count variable indicating number of pain medications used by each participant.
Pain Intensity
Pain intensity was assessed with the adapted Brief Pain Inventory (BPI). 64, 65 Participants rated their current, worst, and average pain intensity during the past 24 hours on an 11-point Numeric Rating Scales ranging from 0 (no pain at all) to 10 (pain as bad as you can imagine). A composite score, "characteristic pain," was calculated by multiplying the mean of these 3 pain items by 10, for a possible range of 0 to 100, with higher scores indicating more pain intensity. This approach captures a more reliable hierarchy of pain intensity than using a single rating of average, current, or worst pain alone. 66 The Cronbach α for this composite pain intensity score was 0.82 in this sample.
Pain Distribution
Pain distribution was assessed with the body diagram of the BPI. 64, 65 Participants were presented with 2 figures depicting the front and back of the body with "right" and "left" sides of the body labeled and were instructed to "shade the areas where you feel pain. Put an X on the area that hurts the most." Similar to previously developed coding method, 67 a diagram with lines for boundaries between body areas was developed to indicate 49 distinct body regions [back/front/left/right: shoulder, upper arm, lower arm, hand, upper leg, lower leg; left/right: chest, upper back, lower back, knee, elbow, pelvis, buttock, foot; front/back: head, neck; sternum, abdomen, sacrum, lower back, upper back (for markings indicating specific midline pain in these regions)]. A single point (1) was marked for each body region that was shaded. Two research assistants independently coded all body diagrams using the same boundary coding diagram and discrepancies were identified and reconciled by the first author. Points were summed to compute a total pain distribution score, ranging from 0 to 49, where higher scores indicate more widespread pain.
Depressive Symptoms
Depressive symptoms were assessed with the Patient Health Questionnaire-9 ([PHQ-9; 68, 69 ]. Respondents rated how often they had been bothered by 9 depressive symptoms in the last 2 weeks on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). Items were summed to produce a symptom-severity score with a range of 0 to 27, where higher values reflected worse depressive symptomatology. 69 The scale demonstrated good internal reliability in the sample with a Cronbach α of 0.84.
Chronic Pain Acceptance
Chronic pain acceptance was assessed with the Chronic Pain Acceptance Questionnaire (CPAQ) 38 which consists of 20 items in 2 subscales: activities engagement (11 items) and pain willingness (9 items). The activities engagement subscale measures behavioral participation in life activities in a way that is not determined or influenced by pain, including items such as "I am getting on with the business of living no matter what my level of pain is." The pain willingness subscale measures responses to pain that do not reflect controlling or avoiding pain and includes items such as, "I need to concentrate on getting rid of pain" (items reverse scored). Participants rated the extent to which each item applied to them on a scale from 0 (never true) to 6 (always true). Items were summed for a total scale score ranging from 0 to 120, where higher scores indicate more pain acceptance. Previous studies support the validity, factor structure, and reliability of the CPAQ. 38, 48 The Cronbach αs were 0.90 for the total scale (20 items), 0.86 for the pain willingness subscale (9 items), and 0.86 for the activities engagement subscale (11 items) in this sample.
Data Analyses
Descriptive statistics for study variables were calculated to analyze data distribution characteristics. Primary 
study hypotheses were examined using Poisson regression models for total pain medications (counts of medications). Binary logistic regression was used for opioid use and gabapentin use (used yes/no). All regression models included characteristic pain intensity, pain distribution, and depressive symptomatology (PHQ-9 total score) as covariates and were treated as scale variables. All analyses were completed using IBM SPSS Statistics for Windows, Version 24.0 (IBM Corp., Armonk, NY).
RESULTS
Sample Descriptive Statistics
In total, 133 persons with SCI were enrolled in the study (UM, n = 71; WSU/RIM, n = 29; UW, n = 33) and completed baseline assessments. Two did not provide complete responses on the CPAQ and 11 did not complete the medication table; therefore, data from 120 participants were analyzed for this study. Those included in the study did not differ from those who were not in terms of age ( Figure 1 shows that reporting ≤ 10 painful body areas was common, whereas a sizeable minority (n = 35; 29.1%) reported > 10 painful body regions. Scores on the PHQ-9 indicate a sample average in the "mild depression" range (mean, 7.86; SD, 5.59; range, 0 to 24); 34.4% reported no/ minimal depressive symptoms, 32.8% had mild, 20.8% had moderate, 9.6% had moderately severe, and 2.4% had severe depressive symptoms. Average pain acceptance (total score) was 66.07 (SD, 19.84; range, 13 to 112) with subscale averages for pain willingness of 25.89 (SD, 10.65; range, 1 to 53) and for activities engagement of 40.18 (SD, 11.44; range, 6 to 61).
The medications reported by participants and their classifications are given in Table 1 . In total, 54 (45.0%) reported taking a gabapentinoid and 49 (40.8%) reported taking at least 1 opioid medication. Of those who reported taking opioid medications, 10 (12%) were taking 2 opioid medications and 2 (1.7%) were taking 3 opioid medications; because few people used multiple opioids, opioid use was dichotomized (yes/no). Figure 2 shows the distribution of the number of pain medications reported. Notably, 22.9% (n = 30) reported taking no pain medications, and 68.7% (n = 90) reported taking between 1 to 3 different medications for pain.
Regression Models Results
Regression models for total pain acceptance scores indicated that higher pain acceptance was related to a significantly lower number of pain medications used, above and beyond the effects of pain intensity, number of painful body areas, and depressive symptoms. Among these covariates, only number of painful body areas was significantly associated with medication use, such that more painful body areas corresponded to greater pain medication use. Total pain acceptance scores were significantly associated with opioid use such that higher acceptance scores were related to lower risk of opioid use. For every 1-unit increase in the pain acceptance score (with scores ranging from 0 to 120), there was a 3% lower odds of using an opioid. Pain acceptance was not associated with gabapentinoid use, although the association approached statistical significance (P = 0.08). In these regression models, few of the covariates corresponded with pain medication use. None of the covariates, that is, pain intensity, pain distribution, and depressive symptoms, were significantly related to opioid use. Only number of painful body areas was positively associated with gabapentin use (Table 3) . In contrast to expectations, neither pain willingness nor activities engagement were independently significantly associated with the sum of pain medications, above and beyond the effects of relevant covariates; among these covariates, only pain distribution was related to total number of pain medications. Activities engagement but not pain willingness was significantly and negatively related to opioid use such that for every 1-unit increase in the activities engagement subscale score, there was a 6% decreased odds of taking an opioid medication. None of the covariates in the model were related to opioid use. In contrast, pain willingness but not activities engagement was significantly and negatively associated with gabapentin use such that for every 1-unit increase in the pain willingness subscale score, there was a 6% decrease in the odds of taking a gabapentinoid. In this model, pain distribution was the only covariate significantly related to gabapentin use (Table 4) .
DISCUSSION
Serious risks associated with pain medications, particularly for some clinical groups such as SCI, coupled with low efficacy for management of chronic pain point to the need to identify low-risk approaches for managing pain that can decrease reliance on pain medications. In this study we examined whether chronic pain acceptance, which is related to myriad positive outcomes, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] has the added benefit of being related to diminished reliance on pain medication in people with chronic pain and SCI. Results from this study suggest that greater pain acceptance is associated with using fewer pain medications overall, and with a lower likelihood of using opioid medications and gabapentinoids (when considering pain willingness, specifically). These associations were above and beyond the effects of pain intensity level, pain distribution, and depressed mood.
In contrast to expectations that pain willingness would be the more robust component of pain acceptance, both pain acceptance components played roles in predicting pain medication use. In terms of the total pain medication outcome in particular, the 2 components demonstrated an synergistic relationship, as neither subscale on its own was a significant independent predictor of total pain medication use. When the components of pain acceptance were disaggregated into their respective subscales, the association with the use of opioids and gabapentinoids suggests a rather nuanced relationship. Pain willingness was independently and negatively related to gabapentin use, but activities engagement was not. In contrast, the activities engagement subscale was the more robust component in terms of predicting opioid use, but not gabapentinoid use. Given that pain acceptance subscales were inconsistent in their respective relationship to various medication types, further examination of these specific associations and more in depth exploration of what may explain them is warranted.
Pain intensity did not have a robust association-either positive or negative-with pain medication usage in any of the regression models. This is interesting from a number of perspectives, whether following the assumption that greater pain intensity would relate to greater pain medication use, as found in other populations, 70 or that greater pain medication use would be related to lower pain ratings (in cases of successful analgesia). It is plausible that this lack of association reflects a combination of both such that those with higher pain use more medications, and experience some level of relief from those medications. Alternatively, pain intensity may not be the primary driver of pain medication use. In this sample, pain distribution was a more robust predictor than pain intensity with respect to the number of pain medications taken. This may be explained by the notion that greater pain distribution may indicate different types of pain, such as pain due to nociceptive and neuropathic pain in the same individual, which may call for different medications. The association of pain distribution to gabapentinoid use makes sense due to the fact that this class of drugs is used primarily to treat neuropathic pain, which classically presents as pain that is widespread and characterized by a progressive spread of pain across regions of the body, often following dermatomal or peripheral never pathways. 71, 72 In this sample, with each additional painful body area there was a corresponding 8% increase in the odds of gabapentinoid use. Neuropathic pain was not assessed in this study, so its role cannot be directly assessed. Taken together, these findings suggest that it is not enough to simply ask about pain intensity level characterizing an individual's pain problem. Although the ability to assess pain distribution with "body maps" has long been an option, 65, 67, 73 and there have been recent efforts to develop and validate new measures of pain distribution, 74 relatively few published pain studies examine pain distribution and most pain research continues to be focused on pain intensity as the main outcome of interest. 75 Although depression was not of primary interest in the analysis, it is interesting to note that it was not related to pain medication use, particularly given past findings of associations between emotional distress and medication use and misuse. 76, 77 This includes using analgesic medication to "self-medicate" nonpain symptoms, 78 and the fact that the affective component of pain, rather than pain intensity, has been found to be the primary predictor of analgesic use in an SCI sample. 14 Findings from this current study suggest that depression does not play a prominent role in the use of pain medication for chronic pain in SCI.
There are a number of ways to characterize pain medication use. We chose a rather straightforward approach of considering how many different pain medications a person took and whether or not a person used an opioid or gabapentinoid medication, 2 medication categories that are commonly used to treat pain in SCI and with relatively highrisk profiles. We chose the total number of pain medications based on the assumption that each additional pain medication confers an additional and unique side-effect risk profile in addition to potential drug interactions. From a clinical standpoint, the use of 4 different pain medications, for example, demonstrates a different reliance on pain medication than the use of a single pain medication, even if it is particularly potent. Using multiple pain medications requires a higher level of vigilance to administration for determining whether and when to take pro re nata (PRN) medications and non-PRN medications. In the case of opioid medications, 1 common way to quantify usage is through calculating daily morphine equivalence (ME). Use of MEs for clinical and research purposes is not without controversy, due in part to a lack of universally supported ME conversion factors 79 and individual differences in how effective and risky opioids are (eg, an effective dose for one may be the dose at which another person has an overdose). 80 In addition, the cross-sectional design of this study could not assess dosage taken on a day-to-day basis, and that not every participant reported opioid dosage when taking those medications, further supporting our decision to treat opioid use as binary variable. We had a similar rationale for characterizing gabapentinioid usage as a dichotomous variable. There is substantial need to develop standardized ways of quantifying medication use in a way that will produce the most valid and meaningful data for individuals. 80 
Study Strengths and Limitations
The generalizability of study findings to the broader population of people with chronic pain and SCI is not clear. We excluded volunteers who could not use the study device, so the relevance of these findings to individuals with greater physical impairment may be limited. Because chronic pain was not operationalized during screening and recruitment, it is possible that the study sample included people with pain duration <3 months, the typical temporal criteria for chronic pain. Data on participation rate (eg, declines, screen fails) were not collected at the study sites. We did not assess previous exposure to behavioral treatment for pain, and thus cannot speak to the degree to which pain acceptance was naturally occurring versus learned. Chronic pain in SCI is especially complex due to the multiple and concurrent ways it often presents, and often in the context of other comorbid conditions and physical symptoms (eg, fatigue) 21 ; therefore research conducted in SCI calls for replication in other populations to assess broad-based relevance of the findings. This is a cross-sectional study that assessed pain medication use in general, although day-to-day fluctuations in medication use are expected. Future studies that assess daily contributions of pain self-management strategies to day-to-day variability in pain medication consumption are needed and would provide a much more nuanced examination of how people use available pain coping tools, including medication, in everyday life. Moreover, we relied on self-report of current pain medication use; although we had access to the medical records of all participants we did not collect medication data at the time of the study. In our opinion self-report constituted a more reliable assessment of what participants were actually taking at the time of data collection given the difficulties in recreating historical medication regimens from medical records and given the possibility that the medications noted as prescribed in the medical record may not have been filled or taken by the patient. Furthermore, over-the-counter medications are usually not noted in the medical record and medications listed as active in the medical record may have been discontinued. Given that this analysis used cross-sectional data, conclusions about causal direction cannot be made.
Future Directions
Previous studies have shown that pain acceptance increases as a result of acceptance-oriented interventions, such as ACT and MBSR function, 28,33-36 cognitive-behavioral therapy for pain, 31 as well as multidisciplinary pain treatment programs. 32 Given that acceptance appears readily modifiable through multiple behavioral/psychosocial treatment modalities, future research on the impact of changes in acceptance on alterations in pain medications is a logical next step to build on these preliminary results. Unfortunately, psychological interventions for pain are used at a much lower rate in those with SCI compared with the use of medication and interventional treatments, 10, 12 despite the fact that there is growing evidence that psychological interventions result in significant reductions in pain and increases in functional outcomes in SCI. [81] [82] [83] Although it is difficult to make firm clinical recommendations based on these initial findings without replication, they do raise the possibility that reliance on pain medications could be reduced as a result of treatment that increased pain acceptance. Given the riskier side-effect profile of medications compared with behavioral/psychological interventions, integration of pain acceptance interventions into practice may not only reduce the potential complications in an already complex condition, but improve outcomes and even preclude the initiation of multiple pain medications, particularly opioids.
Individuals with pain typically use a number of different management approaches. These can include a combination of taking pain medication(s), undergoing interventional procedures, and engaging in behavioral self-management strategies. Among these approaches, only behavioral self-management strategies present few known risks or side-effects, whereas there can be numerous risks for medically based treatments. These findings highlight the need for future trials of interventions aimed at increasing acceptance to assess medication use as a treatment outcome and for all behaviorally based trials to consider how adoption of more self-management strategies may correspond with abandonment of medically based pain management tools that may become unnecessary and undesirable in cases where the approach also causes problems (eg, side-effects) for the patient. Although this cross-sectional study provides important preliminary evidence for an association between pain acceptance and pain medication use, future research that uses longitudinal and/or daily process (eg, daily diary, ecological momentary assessment) methods are necessary to provide insights as to how people utilize available pain selfmanagement strategies in real life. Future studies may also incorporate medication categories that were not included in this study, but may have an effect on chronic pain in persons with SCI, particularly antispasticity medications.
CONCLUSIONS
This study expands on the literature supporting the important role of pain acceptance in chronic pain management, and suggests that greater pain acceptance is related to lower pain medication use in person with chronic pain and SCI. A better understanding of this relationship has important clinical implications as to where clinicians may focus their efforts and how they educate patients regarding the multimodal treatment approach to managing chronic pain. Given substantial concerns regarding the limited efficacy and adverse effects of pain medications for chronic pain in both the SCI and general population, and the safety profile and efficacy of psychological interventions, improving pain acceptance may be a promising strategy that can reduce reliance on pain medications and improve pain to enhance overall health and well-being in persons with SCI.
